Biogen Idec's long-acting beta interferon moves ahead in MS PMLiVE Biogen Idec's also sells Tysabri (natalizumab) for MS, which is expected to remain an important treatment option for some patients, and is also bringing a new anti-CD-25 antibody called daclizumab through late-stage development in partnership with Idec. |
